You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: INOVODEL, INC.            Topic: NHLBI

    SUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Automating Assessment of Contextualization of Care During the Clinical Encounter

    SBC: Institute for Practice and Provider Performance Improvement, Inc.            Topic: 600

    Background: Large scale studies have demonstrated that when patients struggle with life challenges that complicate their care (e.g., a lack of social support, competing responsibilities, or financial hardships), health care providers can improve health care outcomes and lower costs if they attempt to identify these “contextual factors” and address them in their care plan – a process termed ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Motion-Resistant Background Subtraction Angiography with Deep Learning:Real-Time, Edge Hardware Implementation and Product Development

    SBC: CLEARVOYA LLC            Topic: NHLBI

    Catheter Digital Subtraction Angiography (DSA) is an imaging technique that was developed in the 1980s to allow physicians to visualize blood vessels. Today, this technology is utilized for minimally-invasive interventions that treat numerous devastating pathologies, including stroke and myocardial infarction, diseases that disproportionally impact underserved minority patient populations.Catheter ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Pigment Sensing Pulse Oximeter Technology for Mitigating Racial Bias in Oxygen Saturation Measurements

    SBC: PENDERIA TECHNOLOGIES, INC.            Topic: 100

    Abstract Wearable pulse oximetry sensors are among the most ubiquitous medical technologies used in healthcare. Clinicians rely on pulse oximeters to monitor patient health during disease states and medical procedures. However, numerous studies have shown this technology to be racially biased; hypoxemia is three times more likely to go undetected in patients with dark skin compared to those with l ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection

    SBC: Covira Surgical            Topic: NIAID

    SUMMARY Covira Surgical, Inc. is developing CS-0003, a first-in-class, orally administered non-antibiotic therapy for preventing infections in patients undergoing gastrointestinal (GI) surgeries. Despite improved surgical procedures, broad use of antibiotics, mandated asepsis measures, and enhanced recovery programs, post-surgical infections remain a clear and present danger to patients. Surgical ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE

    SBC: SOMATOLYNK, INC.            Topic: NIA

    An estimated one out of eight individuals over the age of 65 has Alzheimer’s disease (AD), with a prevalence of 1-in-3 for those over age 85. There are approximately 5.8 million people in the USA with AD, with a global projection of over 150 million by 2050. There remains a lack of effective treatment to halt disease progression. Somatostatin receptor-4 (SSTR4) represents an innovative and viabl ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. An R2 non-neuroinvasive herpes simplex virus type 2 vaccine

    SBC: THYREOS INC            Topic: NIAID

    PROJECT SUMMARY There is an unmet need for a herpes simplex virus (HSV) vaccine. We propose to develop a live-attenuated HSV-2 vaccine based on our R2 technology platform. R2 vaccines show unprecedented safety and efficacy in animal models, and offer antigenicity superior to subunit/mRNA and single-round vaccine designs. R2 vaccines are also the first live-attenuated alphaherpesvirus vaccines that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Making Mindfulness-Based Cognitive Therapy accessible for underserved pregnant people: Developing Center M for commercialization

    SBC: CENTER MOM, INC.            Topic: 104

    PROJECT SUMMARY/ABSTRACT A highly effective intervention to prevent perinatal depression, mindfulness-based cognitive therapy for perinatal depression (MBCT), exists; however, critical implementation gaps prevent its wide use. And though universally recommended, not all prenatal care clinics effectively screen for perinatal depression (PD). Overcoming current implementation gaps is imperative to a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels

    SBC: Gamma Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT g' (pronounced "gamma prime") fibrinogen (GPF) is an alternative splice isoform of the blood coagulation factor fibrinogen. This fibrinogen variant contains a high affinity binding site for the coagulation factor thrombin that localizes thrombin on the growing blood clot. Thrombin binds to GPF via thrombin's heparin binding site. This allows thrombin to continue forming th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Implantable Microarray Probe for Real-Time Glutamate and GABA Detection

    SBC: ALCORIX CO            Topic: 105

    Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government